Science & Enterprise subscription

Follow us on Twitter

  • Spark Therapeutics, a developer of gene therapies, is gaining access to a technology that programs DNA sequences li… https://t.co/WGboSsrf7U
    about 16 hours ago
  • New post on Science and Enterprise: Gene Therapy Company Exploring DNA Circuit Technology https://t.co/2YUM4DVZRK #Science #Business
    about 16 hours ago
  • A study with lab mice shows an experimental vaccine with engineered bacteria produces antibodies and protects again… https://t.co/3JtSqD1Sa2
    about 20 hours ago
  • New post on Science and Enterprise: Vaccine Stops Lyme Bacteria in Preclinical Test https://t.co/7H0Lc90nRe #Science #Business
    about 20 hours ago
  • Stop the panic porn ... Coronavirus Variants Don’t Have to Be Scary. Still, Mask Up. https://t.co/d6aDu2Ucj6
    about 23 hours ago

Please share Science & Enterprise

Hearing Tech Company Raises New Venture Funds

Smart Ear device and app

A company creating devices that help people with hearing impairments, but without the stigma or cost of hearing aids, is raising $7 million in new venture funds. . . . → Read More: Hearing Tech Company Raises New Venture Funds

Stem Cell Therapy Licensed for Genetic Eye Disease

Red-blue-green eye

A biotechnology company is licensing its stem cell treatments for retinitis pigmentosa, an inherited eye disease, in a deal valued at $252 million. . . . → Read More: Stem Cell Therapy Licensed for Genetic Eye Disease

Blood Cancers Respond to Cord Blood Cells

Katy Rezvani

A small-scale clinical trial shows most patients with two blood-related cancers safely respond to immune system cells derived from umbilical cord blood. . . . → Read More: Blood Cancers Respond to Cord Blood Cells

Infographic – China Closes R&D Funding Gap

R&D spending 2017

A new report from National Science Foundation shows China now ranks a close second to the U.S. in total research and development investments. . . . → Read More: Infographic – China Closes R&D Funding Gap

Synthetic Bio Cancer Immunotherapy Company Acquired

Natural killer cell

A biotechnology company creating synthetic proteins that invoke the immune system to fight cancer is being acquired by drug maker Astellas Pharma. . . . → Read More: Synthetic Bio Cancer Immunotherapy Company Acquired

Trial Shows Nanotech Drug Induces Gluten Tolerance

bread and rolls

Results from a clinical trial show an experimental treatment encourages immune-system tolerance of gluten, preventing intestinal damage from celiac disease. . . . → Read More: Trial Shows Nanotech Drug Induces Gluten Tolerance

Migraine Drug Developer Raises $82.5M in IPO

NASDAQ share price display

A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million in its initial public offering of common stock. . . . → Read More: Migraine Drug Developer Raises $82.5M in IPO

Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Laptops on a table

Japanese pharmaceutical company Sumitomo Dainippon agreed to acquire five biotechnology companies and gain an equity stake in the Roivant Sciences group. . . . → Read More: Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Hearing Loss Cell Therapy Licensed in $625M Deal

Man with headphones

A biotechnology company developing regenerative treatments for various disorders is licensing its lead therapy candidate for hearing loss to Astellas Pharma. . . . → Read More: Hearing Loss Cell Therapy Licensed in $625M Deal

Stem Cell Start-Up Raises $250M in Venture Funds

T-cell lymphocyte

A company begun last year to create cancer therapies from banked, off-the-shelf stem cells is raising $250 million in its first round of venture financing. . . . → Read More: Stem Cell Start-Up Raises $250M in Venture Funds